Christopher Lehmann is an Infectious Disease physician affiliated with University of Chicago. OpenAlex indexes 35 publications with 341 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5841 S Maryland Ave # Mc5065
Chicago, IL 606371443
Telephone
773-702-1000Provider last certified this registry record 12 Jun 2023.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Penem Antibacterial27.7%Meropenem100%Part D<11 patientsPenicillins with extended spectrum25.5%Amoxicillin-Clavulanate Potass100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2026–2026 per NIH RePORTER. The latest:
- Defining the Scope and Consequences of Gut Microbiome Dysbiosis in Hospitalized Patients
University of Chicago
FY2026$185,760K23AI197092
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- P-1569. Microbiome Derived Stool Metabolites Predict E. faecium Expansion in Hospitalized Patients
Open Forum Infectious Diseases
2026 - Digestion-resistant proteins support the healthy metabolite profiles associated with plant-based diets
Proceedings of the National Academy of Sciences
2026 - P-1783. Blood Metagenomic Next-Generation Sequencing and its Impact on Antimicrobial Management
Open Forum Infectious Diseases
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Everett Vokes, MD
University of Chicago
Ralph Weichselbaum, MD
University of Chicago
Mary Rinella, MD
University of Chicago
Hedy Kindler, MD
University of Chicago
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”